Cost-effectiveness analysis of orbital atherectomy plus balloon angioplasty vs balloon angioplasty alone in subjects with calcified femoropopliteal lesions

ClinicoEconomics and Outcomes Research

Volumn 6, Issue 1, 2014, Pages 133-139

  Weinstock, Barry ^a   Dattilo, Raymond ^b   Diage, Tiffini ^c  

^a ORLANDO HEALTH   (United States)

^b St Francis Health Center   (United States)

^c North American Science Association (NAMSA)   (United States)

Author keywords

Cost analysis; Orbital atherectomy; Peripheral vascular disease

Indexed keywords

ARTERY CALCIFICATION; ARTICLE; ATHERECTOMY; CALCIFIED FEMOROPOPLITEAL LESION; CLAUDICATION; COST EFFECTIVENESS ANALYSIS; HEALTH CARE UTILIZATION; HOSPITAL COST; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; ORBITAL ATHERECTOMY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RESTENOSIS;

EID: 84897902756     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S59568     Document Type: Article

References (21)

1. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-S75.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics 2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
3. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47(6):1239-1312.
4. Almahameed A, Bhatt DL. Contemporary management of peripheral arterial disease: III. Endovascular and surgical management. Cleve Clin J Med. 2006;73 Suppl 4:S45-S51.
5. Bishop PD, Feiten LE, Ouriel K, et al. Arterial calcification increases in distal arteries in patients with peripheral arterial disease. Ann Vasc Surg. 2008;22(6):799-805.
6. Fitzgerald PJ, Ports TA, Yock PG. Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound. Circulation. 1992;86(1):64-70.
7. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45(2):312-315.
8. Iida O, Nanto S, Uematsu M, Ikeoka K, Okamoto S, Nagata S. Influence of stent fracture on the long-term patency in the femoro-popliteal artery: experience of 4 years. JACC Cardiovasc Interv. 2009;2(7):665-671.
9. Korabathina R, Mody KP, Yu J, Han SY, Patel R, Staniloae CS. Orbital atherectomy for symptomatic lower extremity disease. Catheter Cardiovasc Interv. 2010;76(3):326-332.
10. Safian RD, Niazi K, Runyon JP, et al. Orbital atherectomy for infrapopliteal disease: device concept and outcome data for the OASIS trial. Catheter Cardiovasc Interv. 2009;73(3):406-412.
11. Makam P. Use of orbital atherectomy treatment in a high-volume clinical practice modifies non-compliant plaque to deliver durable long-term results. J Invasive Cardiol. 2013;25(2):85-88.
12. Shammas NW, Lam R, Mustapha J, et al. Comparison of orbital atherectomy plus balloon angioplasty vs balloon angioplasty alone in patients with critical limb ischemia: results of the CALCIUM 360 randomized pilot trial. J Endovasc Ther. 2012;19(4):480-488.
13. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-e146.
14. Hirsch AT, Hartman L, Town RJ, Virnig BA. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008;13(3):209-215.
15. Dattilo R. The COMPLIANCE 360° Trial: the principal investigator of the COMPLIANCE 360° trial discusses its rationale, study design, and potential therapeutic implications. Endovascular Today. Mar 2010.
16. Safley DM, Lindsey JB, Robertus K, et al. In-hospital outcomes and cost comparison of femoropopliteal reopening strategies. Cardiovasc Revasc Med. 2011;12(5):292-298.
17. Burket MW. Restinosis and the New Health Care Economy. Endovascular Today. 2013:42-48.
18. Robinson WP 3rd, Nguyen LL, Bafford R, Belkin M. Results of secondtime angioplasty and stenting for femoropopliteal occlusive disease and factors affecting outcomes. J Vasc Surg. 2011;53(3):651-657.
19. Egberg L, Mattiasson AC, Ljungstrom KG, Styrud J. Health-related quality of life in patients with peripheral arterial disease undergoing percutaneous transluminal angioplasty: a prospective one-year follow-up. J Vasc Nurs. 2010;28(2):72-77.
20. Kalbaugh CA, Taylor SM, Blackhurst DW, Dellinger MB, Trent EA, Youkey JR. One-year prospective quality-of-life outcomes in patients treated with angioplasty for symptomatic peripheral arterial disease. J Vasc Surg. 2006;44(2):296-302.discussion 302-293.
21. de Vries SO, Visser K, de Vries JA, Wong JB, Donaldson MC, Hunink MG. Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy. Radiology. 2002;222(1): 25-36.